SAM
ORIC icon

Smartleaf Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Smartleaf Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-870
Closed -$9.27K – 2988
2024
Q3 		$9.27K Buy
+870
New +$8.6K ﹤0.01% 1798

Other funds holding ORIC

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Smartleaf Asset Management's ORIC Position: Q4 2024 in Review

Smartleaf Asset Management sold out of Oric Pharmaceuticals (ORIC) in Q4 2024, closing a stake of 870 shares — an estimated $9.27K sold.

Smartleaf Asset Management first reported a position in ORIC in Q3 2024 and held it in 1 quarter. The position peaked at $9.27K in Q3 2024. 129 funds tracked by Wall St. Rank hold ORIC as of Q4 2024.

  • Smartleaf Asset Management reported no remaining Oric Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Smartleaf Asset Management sold 870 Oric Pharmaceuticals shares in Q4 2024, an estimated $9.27K.
  • Smartleaf Asset Management first reported a position in Oric Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Smartleaf Asset Management's Oric Pharmaceuticals position peaked at $9.27K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2024.

Based on Smartleaf Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.